Analysts think BIAF stock price could increase by 236%
Oct 05, 2024, 11:26 AM
-24.73%
What does BIAF do
bioAffinity Technologies, based in San Antonio, Texas, focuses on non-invasive early-stage cancer diagnosis and treatment, employing 75 staff since its IPO on August 26, 2022. Its first product, CyPath Lung, aids in detecting early-stage lung cancer, enhancing patient intervention decisions.
3 analysts think BIAF stock price will increase by 236.26%. The current median analyst target is $6.12 compared to a current stock price of $1.82. The lowest analysts target is $6.06 and the highest analyst target is $6.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.